Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cerenis starts phase III trial of CER-001 in familial primary hypoalphalipoproteinemia

Jan. 29, 2016

Transplanted pancreatic beta-like cells exhibited glucose-stimulated insulin secretion in mice

Jan. 27, 2016

Novo Nordisk announces the launch of Tresiba in the U.S.

Jan. 27, 2016

FDA accepts for review cardiovascular outcomes data for Jardiance

Jan. 26, 2016

Bonviva tablet approved in Japan for the treatment of osteoporosis

Jan. 25, 2016

Phase II results indicate sustained expression with AAT deficiency gene therapy

Jan. 25, 2016

Amgen's Repatha approved in Japan

Jan. 22, 2016

Ajinomoto divulges GS activators

Jan. 22, 2016

Janssen Pharmaceutica describes FFAR1 agonists

Jan. 22, 2016

Coprimary efficacy endpoints met in phase III trial of beloranib for Prader-Willi syndrome

Jan. 21, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...